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Background: Intravenous immunoglobulin (IVIg) is currently in clinical study for Alzheimer’s disease (AD). However,
preclinical investigations are required to better understand AD-relevant outcomes of IVIg treatment and develop
replacement therapies in case of unsustainable supply.
Methods: We investigated the effects of IVIg in the 3xTg-AD mouse model, which reproduces both Aβ and tau
pathologies. Mice were injected twice weekly with 1.5 g/kg IVIg for 1 or 3 months.
Results: IVIg induced a modest but significant improvement in memory in the novel object recognition test and
attenuated anxiety-like behavior in 3xTg-AD mice. We observed a correction of immunologic defects present in
3xTg-AD mice (−22% CD4/CD8 blood ratio; −17% IL-5/IL-10 ratio in the cortex) and a modulation of CX3CR1+ cell
population (−13% in the bone marrow). IVIg treatment led to limited effects on tau pathology but resulted in a
22% reduction of the soluble Aβ42/Aβ40 ratio and a 60% decrease in concentrations of 56 kDa Aβ oligomers
(Aβ*56).
Conclusion: The memory-enhancing effect of IVIg reported here suggests that Aβ oligomers, effector T cells and
the fractalkine pathway are potential pharmacological targets of IVIg in AD.
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CX3CR1Background
The main neuropathological hallmarks of Alzheimer’s dis-
ease (AD) are synaptic dysfunction, neuron loss, amyloid
plaques, composed of aggregated Aβ peptide, and neuro-
fibrillary tangles, containing hyperphosphorylated forms of
the protein tau [1]. Preclinical findings in animal models
indicate that active and passive immunization against clas-
sical molecular markers of AD might represent suitable
therapeutic strategies [2,3]. However, in clinical trials, Aβ-
targeted immunotherapies have shown limited efficacy
against AD cognitive symptoms [4,5], and have been* Correspondence: Frederic.Calon@pha.ulaval.ca
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unless otherwise stated.associated with various adverse effects such as microhe-
morrhages, vasogenic oedema and aseptic meningitis [6].
Intravenous immunoglobulin (IVIg), which is com-
posed of over 98% human immunoglobulin G (hIgG), is
used in the treatment of an increasing number of dis-
eases and is generally safe and well tolerated [7]. Natural
autoantibodies against Aβ peptide and oligomers have
been reported in the blood of healthy individuals and in
IVIg preparations [8,9]. Initial evidence of IVIg efficacy
comes from pilot studies in which IVIg improved cogni-
tion and reduced Aβ in the cerebrospinal fluid (CSF) in
AD patients [10,11]. Results from a large phase III clinical
trial (ClinicalTrials.gov identifier: NCT00818662) pre-
sented at the 2013 Alzheimer’s Association International
Conference indicate that an 18-month treatment with
IVIg acted on plasma and positron emission tomography
(PET) biomarkers, but did not improve cognitive scores inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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However, subgroup analyses unveiled improved cognitive
endpoints in APOE4 carriers [12], suggesting clinical
benefit in a subpopulation representing almost 40% of AD
patients [13]. These large clinical trials also confirmed the
good safety profile of IVIg in AD patients [12,14]. Finally,
a retrospective case-controlled study using anonymous
medical data indicates that IVIg-treated patients have a
42% lower incidence rate of dementia than an untreated
population [15]. Overall, these preliminary data strongly
suggest that further clinical studies better powered for
subgroup analyses and using larger doses of IVIg are war-
ranted in AD.
Regardless of the results of the clinical assays, the
amount that would be needed to treat the 24 million pa-
tients afflicted worldwide [16] precludes a widespread
use of this product which has to be purified from the
plasma of healthy donors. Preclinical research in animal
models is thus essential to identify potential pharmaco-
logical targets, and to develop a replacement therapy to
avoid a massive shortage of plasma that would ensue the
use of IVIg as a first-line treatment for AD. The present
investigation aimed at replicating the beneficial effects of
IVIg in the 3xTg-AD mouse model to decipher its po-





Group/treatment Age at sacr
Experiment I




27 i.p. injections (two/week) 12.0 ± 0.1 m
of age
NonTg: ctrl (n = 8, 50% F)
3xTg-AD: ctrl (n = 13, 54% F)/
1.5 g/kg IVIg (n = 12, 50% F)
Ctrl/vehicle: endotoxin free
glycine 0.2 M pH 4.25
Experiment II
12.9 ± 0.2 and




27 i.p. injections (two/week)
(12.9 ± 0.2 months of age)
15.9 ± 0.2 m
of age
NonTg: ctrl (n = 8, 50% F)/
1.5 g/kg IVIg (n = 8, 50% F)
3xTg-AD: ctrl (n = 14, 50% F)/
1.5 g/kg IVIg (n = 13, 46% F)
1-month
treatment
Nine i.p. injections (two/week)
(14.8 ± 0.2 months of age)
NonTg: ctrl (n = 8, 50% F)
3xTg-AD: ctrl (n = 14, 50% F)/
1.5 g/kg IVIg (n = 13, 46% F)
IVIg, Gamunex™ (Grifols Canada Ltd., Mississauga, ON, Canada). 3xTg-AD, triple-tran
immunosorbent assay; ELISPOT, enzyme-linked immunosorbent spot; F, female; i.p.,
NOR, novel object recognition.Methods
Animals and IVIg treatment
Triple-transgenic (3xTg-AD) and age-matching non-trans-
genic (NonTg) mice were developed by Oddo and col-
leagues [17] and bred in our animal facility. The 3xTg-AD
mouse harbors three mutant genes, namely genes coding
for the human beta-amyloid precursor protein (APPswe),
presenilin-1 (PS1M146V) and tau (P301L) [17], and is used
as a model for AD since it replicates Aβ and tau path-
ologies, and displays cognitive deficits. The human APP
and tau-independent transgene constructs have been
co-injected in embryos harvested from mutant homozy-
gous PS1M146V knock-in mice. Both human APP and tau
transgenes are under the control of the Thy1.2 regulatory
elements, co-integrated in the same locus and therefore
inherited together [17]. The Laval University Animal
Research Committee (Québec, QC, Canada) approved
all procedures. The treatment and analysis schedule is
presented in detail in Table 1. Briefly, 3xTg-AD mice
received intraperitoneal administrations of 1.5 g/kg
IVIg (Gamunex™; Grifols Canada Ltd., Mississauga, ON,
Canada) or the equivalent volume of vehicle (0.2 M gly-
cine pH 4.25, endotoxin free) twice a week for 1 month
(nine injections, only for 16-month-old animals at sac-
rifice) and 3 months (27 injections). Mice were killed atifice Behavioral tests Postmortem analyses
onths Novel object recognition
(NOR) task
Brain: ELISA quantification, Western
blots, immunohistochemistry
and immunofluorescence
Dark-light box emergence test Blood, whole blood and plasma:
saphenous vein blood
(after 25 injections),
flow cytometry and ELISA
Bone marrow, cells: flow
cytometry
Splenocytes: flow cytometry and
ELISPOT
onths NOR task Brain: ELISA quantification,
Western blots
Barnes maze (3xTg-AD
mice, 3-month treatment only)
Blood, whole blood and plasma:
intracardiac blood (at sacrifice),
flow cytometry and ELISA
Open field
sgenic mouse model of Alzheimer’s disease; ctrl, control; ELISA, enzyme-linked
intraperitoneal; IVIg, intravenous immunoglobulin; NonTg, non-transgenic;
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fied, the age used in the text and Figures refers to the
age of the animals at sacrifice at the end of treatment.
Behavioral tests
The effects of IVIg treatment on memory and anxiety-
like behavior in 3xTg-AD and NonTg mice were evalu-
ated using a series of cognitive tests. Behavioral tests
were performed during the 2 weeks preceding sacrifice
with a recovery time of at least 48 hours between every
task and a 24-hour delay after the last IVIg injection to
reduce stress. The protocols used for all behavioral test-
ing were based on pilot studies previously performed in
our colony of 3xTg-AD mice [18,19].
The novel object recognition (NOR) test has been de-
veloped to study learning and memory in rodents and is
based on their spontaneous tendency to have more in-
teractions with a novel than a familiar object [18]. Dur-
ing the familiarization period, the mouse was placed in a
standard cage (29.2 cm × 19 cm × 12.7 cm) containing
two identical objects for 5 minutes and returned quickly
to its housing cage. Recognition memory was tested
1 hour later by exposing the animal to one familiar and
one novel object. The time spent exploring and sniffing
each object was recorded. The NOR index was deter-
mined as the time spent interacting with the novel ob-
ject divided by the total time of exploration during the
testing phase. Animals whose exploration time was con-
sidered insufficient to allow recognition (<10 seconds
per object) during the familiarization phase were ex-
cluded from analysis.
The dark-light box emergence test was used to evaluate
the anxiety-like behavior and was performed as previously
described [20]. Mice were initially placed in the center of
the dark chamber and had free access to the illuminated
chamber. The total time spent in the illuminated chamber
and the number of alternation between sides were recorded
for 5 minutes. A reduction in the number of alternations
or in the time spent in the illuminated compartment was
interpreted as increased anxiety.
Mice were tested for spatial memory using a Barnes
maze (San Diego Instruments, San Diego, CA, USA)
[21]. The 3xTg-AD female mice were tested individually
over a 5-day period. Each animal was placed in the cen-
ter of the maze and subjected to aversive stimuli (bright
light and noise). The mouse was given the opportunity
to leave the maze through the escape hole. On training
days 1 to 4, mice were subjected to 4 × 3-minute trials
per day (inter-trial interval time of 20 minutes). For
probe trial on Day 5, mice were tested during a 90-
second period. Animals were evaluated for their ability
to remember the fixed position of an escape compart-
ment. The latency and number of errors before reaching
the target hole were recorded for the training and probephases. For more consistency between animals, all train-
ing sessions took place between 7:00 and 12:00 a.m. The
mice were subjected to the Barnes maze at the end of
the treatment period and the animals were injected with
IVIg on Day 2 and 4 of the training session, late in the
afternoon to reduce the stress, and sacrificed on Day 5,
after the probe trial.
The open field testing measured the general locomotor
activity. The open field apparatus consists of ten Plexi-
glas cages with white translucent walls (80 cm × 80 cm).
Movements were tracked by the automated recording of
photobeam breaks (San Diego Instruments) to measure
horizontal (for example, distance traveled) and vertical
activity (for example, rearing). Mice were placed indi-
vidually in the center of the open field and movements
were recorded for 1 hour.
Reagents and antibodies
All biochemical reagents were purchased from JT Baker
(Phillipsburg, NJ, USA) unless otherwise specified. Anti-
bodies used for Western blot and flow cytometry ana-
lyses are described in Additional file 1: Table S1.
Tissue preparation for postmortem analyses
Terminal intracardiac perfusion was performed under
deep anesthesia (100 mg/kg ketamine and 10 mg/kg
xylazine). For biochemical analyses, parietotemporal cor-
tices were homogenized and centrifuged sequentially to
generate a cytosolic fraction (Tris-buffered saline (TBS)-
soluble, with protease and phosphatase inhibitors, con-
taining both intracellular and extracellular proteins), a
membrane fraction (lysis buffer-soluble (150 mmol/L
NaCl, 10 mmol/L NaH2PO4, 0.5% sodium deoxycholate,
0.5% sodium dodecyl sulfate, 1% Triton X-100), with
protease and phosphatase inhibitors, containing both
nuclear and membrane-bound proteins) as well as an in-
soluble fraction (formic acid extract), as previously de-
scribed [22]. Fractions were kept at −80°C until needed. A
commercial enzyme-linked immunosorbent assay (ELISA)
was used to quantify Aβ40 and Aβ42 peptides according
to the manufacturer (Wako, Osaka, Japan). Protein con-
centration was determined using the bicinchoninic acid
assay (Pierce, Rockford, IL, USA).
Brain cytokine and chemokine concentrations were
determined with a multiplex ELISA (Q-Plex™ Mouse
Cytokine – Screen (16-plex); Quansys Biosciences, Logan,
UT, USA) in parietotemporal cortex homogenates from
12-month-old mice after a 3-month treatment with IVIg
and normalized for IL-10 concentration. The following cy-
tokines and chemokines were analyzed: IL-1α, IL-1β, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17, TNFα,
granulocyte-macrophage colony-stimulating factor (GM-
CSF), regulated on activated, normal T cell expressed and
secreted (RANTES), monocyte chemoattractant protein-1
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matory protein 1α (MIP-1α).
For immunofluorescence and immunohistochemistry
staining, a brain hemisphere was recovered from female
12-month-old mice, fixed in 4% paraformaldehyde
(PFA) for 48 hours and incubated in 20% sucrose at 4°C
for >72 hours. The brain was cut on a frozen micro-
tome in 25-μm thick sections and stained. For quantifi-
cation of amyloid plaques, free-floating sections were
first incubated for 15 minutes in 2% H2O2 and blocked
with 1% normal goat serum and 0.4% Triton X-100 in
PBS. Sections were then incubated overnight at 4°C,
with mouse anti-human APP antibody (clone 6E10).
After the overnight incubation, sections were washed in
PBS and incubated for 1 hour with biotin-conjugated
anti-mouse antibody at room temperature. The sections
were further washed and placed in a solution contain-
ing an avidin/horseradish peroxidase (HRP) complex
(ABC Elite Kit; Vector Laboratories, Burlington, ON,
Canada) for 30 minutes at room temperature. The bound
peroxidase was revealed with 0.3 mg/mL 3-amino-9-ethyl-
carbazole (Sigma-Aldrich, St Louis, MO, USA) and 0.03%
hydrogen peroxide in acetate buffer. Extensive washings
in PBS stopped the reaction. The sections were coun-
terstained with hematoxylin solution, Gill No. 2 (Sigma-
Aldrich), and coverslipped with Mowiol mounting
media. The area occupied by extracellular staining was
quantified in a blinded fashion on five sections of a 1/10
series from bregma, approximately −3.1 mm to −4.1 mm
in the mouse brain atlas [23]. At this age, amyloid plaques
are present in the hippocampus, mostly in the subiculum.
After delineating the subiculum at low magnification
(4× objective) the contour of the plaques was per-
formed at higher magnification (10× objective) and the
areas were measured using Neurolucida software (MBF
Bioscience, Williston, VT, USA). For tau, microglia
(ionized calcium-binding adaptor molecule 1 (Iba1))
and APP detection with immunofluorescence labeling,
mouse anti-human tau (clone HT7; ThermoFisher Sci-
entific Inc., Pierce Antibodies, Rockford, IL, USA),
rabbit anti-Iba1 (Wako) or mouse 6E10 antibodies, re-
spectively, were used as primary antibodies, followed by
detection with the appropriate Alexa Fluor-labeled sec-
ondary donkey antibody (all from Life Technologies,
Burlington, ON, Canada). The nuclei were counter-
stained with 4′, 6-diamidino-2-phenylindole (DAPI;
ThermoFisher Scientific Inc.). Finally, sections were
mounted on ColorFrost Plus slides, treated with 0.5%
Sudan black (in 70% methanol) for 5 minutes and cov-
erslipped with Mowiol mounting media.
Flow cytometry
Fluorochrome-conjugated antibodies were used to study
the expression of cell surface markers and human IgG inblood, spleen and bone marrow cells (Additional file 1:
Table S1). Cells were acquired and analyzed using a
CyFlow ML (Partec North America, Inc., Swedesboro,
NJ, USA) cytometer and FCS Express software (De Novo
Software, Los Angeles, CA, USA).
ELISPOT
To determine whether the injection of IVIg triggered an
anti-human IgG immune response, an enzyme-linked
immunosorbent spot (ELISPOT) test was performed, as
previously described [24]. Briefly, splenocytes isolated by
dissociation of the spleen at sacrifice were unfrozen,
washed, counted, plated on human IgG-coated wells
(Multiscreen®HTS filter plate; Millipore Corporation,
Billerica, MA, USA) and left immobile for antibody se-
cretion. After washing the cells, anti-human-specific
mouse immunoglobulins were detected. Each spot was
counted under a dissection microscope and considered
as a single anti-human IgG-specific B cell clone.
Statistical analyses
Results for experimental groups are presented as the
mean ± SEM. Homogeneity of variances was assessed for
all data using the Bartlett’s test. In cases of equal vari-
ance, statistical differences were determined using one-
way analysis of variance (ANOVA) followed by post-hoc
(Tukey’s or Bonferroni’s) tests for comparisons between
groups. When homogeneity of variances was rejected, a
Welch’s ANOVA followed with the Dunnett’s multiple
comparison test was performed. When a Gaussian distri-
bution could not be assumed, non-parametric Kruskal–
Wallis or Wilcoxon signed-rank tests were used followed
by Dunn’s or Wilcoxon’s post-hoc tests. For comparisons
between two groups, a Student’s t-test with (for non-
homogeneous variances) or without (for homogeneous
variances) the Welch’s correction was performed. One
sample t-test was used to compare the mean NOR index
with random chance (that is, 50%). Finally, coefficients
of correlation and significance of the degree of linear re-
lationship between two parameters were determined
using a simple regression model. The threshold for stat-
istical significance was set to P <0.05. All statistical ana-
lyses were performed using the JMP (version 9.0.2; SAS
Institute Inc., Cary, IL, USA) and Prism 5.0d (GraphPad
Software Inc., La Jolla, CA, USA) software.
Results
Systemically delivered IVIg distributes to the brain and
periphery without inducing a significant immune response
To first evaluate the bioavailability of systemically injected
IVIg, hIgG concentrations were measured with a specific
ELISA in the brain and plasma of 16-month-old 3xTg-AD
and NonTg mice after a 3-month treatment (Figure 1A,B).
In the plasma, we observed a mean concentration of
Figure 1 Biodistribution of IVIg after systemic injections:
absence of specific immune response. Concentrations of human
IgG were evaluated in the (A) plasma, (B) parietotemporal cortex
and (C) splenocytes of NonTg and 3xTgAD mice after a 3-month
treatment with IVIg (1.5 g/kg) or vehicle. The concentrations of IVIg
were measured in plasma and parietotemporal homogenates from
intracardially-perfused 16-month-old mice, using a specific ELISA.
MFI quantification of extracellular human IgG on CD45+ splenocytes
was used to determine the presence of IVIg in splenocytes of
12-month-old mice. Note that the MFI of the control groups was
equivalent to the isotypic control and autofluorescence. Data are
presented as the mean ± SEM of 7 to 8 NonTg and 11 to 13 3xTg-AD
animals. One-way ANOVA followed by Tukey’s multiple comparison
test. ***P <0.001 versus control groups. (D) Repeated injections of IVIg
did not induce a significant anti-human-specific immune response as
shown with human-specific ELISPOT results. Data are presented as the
percentage of splenocytes secreting human IgG-specific antibody of 7
to 10 animals treated for 3 months and sacrificed at 12 months of age.
Statistics: one-way ANOVA. 3xTg-AD, triple-transgenic mouse model of
Alzheimer’s disease; ANOVA, analysis of variance; ctrl, control (vehicle);
ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G;
IVIg, human intravenous immunoglobulin; MFI, mean fluorescence
index; n.d., not detected; NonTg, non-transgenic.
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3xTg-AD and NonTg mice (Figure 1A), whereas 21.9 ±
1.6 ng/mg tissue and 21.7 ± 3.2 ng/mg tissue were de-
tected in the cortex of 3xTg-AD and NonTg animals,
respectively (Figure 1B). Extracellular IVIg was also de-
tected in CD45+ splenocytes using flow cytometry ana-
lyses, with a mean fluorescence index (MFI) of 28.2 ±
1.2 for 12-month-old treated 3xTg-AD mice compared to
7.5 ± 0.3 for untreated controls (Figure 1C). To evaluate
the extent of a possible adaptive immune response to
hIgG in treated mice, we next performed ELISPOT ana-
lyses. There was no significant increase in the frequency
of hIgG-specific antibody-secreting cells among spleno-
cytes (Figure 1D) from 12-month-old 3xTg-AD mice
following a 3-month IVIg treatment (0.0002% ± 0.0001%versus 0.0001% ± 0.0001% for IVIg-treated and control
3xTg-AD mice, respectively, P = 0.36). Therefore, our re-
sults suggest that systemically administered IVIg is distrib-
uted in the brain and periphery of treated mice without
displaying significant immunogenicity.
IVIg administration induces a modest improvement in
memory impairment and anxiety-like behavior
To assess the functional consequences of IVIg treat-
ment, 3xTg-AD mice and NonTg littermates were sub-
jected to a battery of behavioral tasks. First, the NOR
index was investigated in 12- and 16-month-old 3xTg-
AD mice after the administration of IVIg for 1 or
3 months (Figure 2A). IVIg injection significantly ame-
liorated the NOR index assessed in 16-month-old ani-
mals for both treatment durations (NOR index: 64.6 ±
3.7 versus 55.8 ± 4.9 in IVIg and control 3xTg-AD mice
treated from 13 to 16 months, respectively) and miti-
gated the anxiety-like behavior in the dark-light box
emergence test in 12-month-old mice (Figure 2B). After
a 3-month treatment, the increased anxiety-like behavior
usually observed in 3xTg-AD compared to NonTg mice
was significant in vehicle-treated, but not in IVIg-treated
animals. Indeed, IVIg treatment prolonged the time
spent in the illuminated compartment (16.1 ± 10.2 versus
50.9 ± 22.7 seconds for vehicle- and IVIg-treated 3xTg-
AD animals, respectively), although the direct compari-
son between IVIg- and vehicle-treated 3xTg-AD mice
did not reach significance threshold (P = 0.054). How-
ever, the treatment did not improve the performance in
the Barnes maze (Figure 2C). Interestingly, whereas the
Barnes maze tests the spatial memory, the NOR index
reflects the recognition memory, two distinct cognitive
functions that were differently affected by IVIg treat-
ment in this study. To rule out a possible correction of
motor deficits by IVIg as the main cause of these effects,
the locomotor activity of the animals was monitored
with an open field test, which showed no difference be-
tween the various groups (Figure 2D).
Effects of IVIg on Aβ, tau and synaptic pathologies
The presence of natural anti-Aβ and anti-tau antibodies
in IVIg preparations has been proposed as a potential
mechanism by which IVIg could serve as a broad-range,
passive immunization agent [8]. As anti-Aβ antibodies
successfully reduced Aβ and tau pathologies along with
cognitive impairment in several animal models [2], we
hypothesized that IVIg might share the same mechan-
ism. Concentrations of soluble and insoluble Aβ40 and
Aβ42 peptides were first determined in homogenates of
parietotemporal cortex with a specific ELISA. When
pooling the results from both the 1- and 3-month treat-
ments, IVIg administration led to a 22% reduction of the
soluble Aβ42/Aβ40 ratio in 16-month-old, but not in
Figure 2 IVIg treatment improves object recognition memory and anxiety-like behavior in 3xTg-AD mice. (A) NOR test was performed by
12-month-old (3-month-treatment, n = 11 to 12 animals per group) and 16-month-old mice (1- and 3-month-treatments, n = 7 to 8 NonTg and
n = 11 to 13 3xTg-AD animals per group. The mean is indicated with a line. One sample t-test. ∞∞P <0.01, ∞∞∞P <0.001 versus random chance
(50%). (B) Dark-light box emergence test was used to evaluate the anxiety-like behavior (n = 8 NonTg and n = 11 to 13 3xTg-AD mice per group,
12 months of age after a 3-month treatment; mean ± SEM). Kruskal–Wallis test followed by Wilcoxon’s multiple comparison test, *P <0.05 versus
NonTg group. (C) Spatial memory deficits were not improved following a 3-month treatment with IVIg as assessed with 16-month-old 3xTg-AD
mice exposed to the Barnes maze. Data are presented as mean escape latency ± SEM of 11 to 13 animals per group. Comparisons between
groups were performed using a one-way ANOVA followed by Tukey’s multiple comparison test. The area under the curve for the mean escape
latency during the training period was also analyzed with a Student’s t-test. Furthermore, the mean escape latency during the probe test was
compared using a Student’s t-test with Welch’s correction. P >0.05 in all statistical tests. (D) The locomotor performance was evaluated with open
field recording in 16-month-old 3xTg-AD mice after a 3-month treatment. The results are shown as the mean ± SEM of n = 7 NonTg and n = 11
to 12 3xTg-AD animals per group. 1mo, 1-month treatment; 3mo, 3-month treatment; 3xTg-AD, triple-transgenic mouse model of Alzheimer’s
disease; ANOVA, analysis of variance; ctrl, control; IVIg, human intravenous immunoglobulin; NonTg, non-transgenic; NOR, novel object recognition.
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effect on insoluble Aβ levels (Figure 3A). In the 16-
month-old animals, two-way ANOVA statistical analysis
also revealed a significant reduction of the Aβ42/Aβ40
ratio following IVIg treatment (P = 0.0293). It is note-
worthy that only the groups with the reduced Aβ42/
Aβ40 showed an improved NOR index. Consistent with
the later absence of effects on insoluble Aβ, quantifica-
tion of extracellular amyloid deposition with 6E10 im-
munohistochemistry showed no impact of IVIg on
plaque accumulation (Figure 3B). The production of Aβ
is the result of the selective cleavage of the membrane
protein APP by α-, β- and γ-secretase into soluble αAPP
and Aβ peptide. Furthermore, the Aβ peptide is prone to
oligomerization into dimers, trimers and dodecamers.
Therefore, we also assessed the effect of IVIg on concen-
trations of total membrane APP, soluble αAPP and Aβ
dodecamer (Aβ*56) by immunoblot analysis in homoge-
nates of parietotemporal cortex, using the 6E10 antibody[25]. The levels of APP and αAPP were stable, but a loss
of over 60% Aβ*56 was found after a 3-month treatment
with IVIg in 3xTg-AD mice at both ages, compared to
vehicle-treated animals (Figure 3C).
Since AD is also associated with severe tau pathology
and loss of synaptic markers [1], we evaluated the effect
of the IVIg treatment on these pathologies. We first im-
munostained 3xTg-AD brains for phosphorylated tau.
Although characteristic immunostaining was observed in
the 3xTg-AD (Figure 4A) but not the NonTg brains, we
failed to detect significant differences in the intensity
of the immunoreactivity. Total tau and several phos-
phorylated isoforms were quantified in the cytosolic
and insoluble fractions of 12- and 16-month-old mice
(Figure 4B), without any consistent effect of IVIg. Simi-
larly, synaptic protein concentrations (Table 2), as mea-
sured by immunoblots in the cytosolic and membrane of
parietotemporal cortices, remained unchanged by IVIg
treatments. These data suggest a role for IVIg in
Figure 3 (See legend on next page.)
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Figure 3 IVIg treatment decreases Aβ42/Aβ40 ratio and 56 kDa Aβ oligomers. (A) Human Aβ40 and Aβ42 peptides were quantified using
specific ELISA in parietotemporal cortex homogenates of 3xTg-AD mice. Aβ concentrations in soluble and insoluble fractions remained unchanged
following IVIg injections in 12-month-old (3-month treatment, n = 11 to 13 mice) and 16-month-old 3xTg-AD mice at sacrifice (pooled 1- and 3-
month-treatment duration, n = 25 animals). The Aβ42/Aβ40 ratio was significantly decreased in the soluble fraction of 16-month-old IVIg-treated mice.
(B) Aβ deposition was analyzed in the hippocampus after immunohistochemistry using 6E10 antibody in NonTg and 3xTg-AD mice. 20× magnification.
Right: graph shows the quantification of the area occupied by extracellular amyloid plaques in four consecutive brain sections of the subiculum of the
hippocampal formation from 12-month-old 3xTg-AD mice treated for 3 months with IVIg or vehicle (n = 11 per group). Red, human APP; blue,
hematoxylin counterstain. (C) The expression of transgenic human APP (membrane fraction) and the soluble αAPP fragment and Aβ*56 oligomers
(cytosolic fraction) were quantified by Western blot analysis with 6E10 antibody in the cortex of 12- and 16-month-old mice treated for 3 months with
IVIg (n = 13 animals) or vehicle (n = 12 to 14 animals). Significant reduction of soluble Aβ*56 oligomers was also observed on IVIg treatment. Examples
of immunoblots are shown for both fractions (bottom right). Values are expressed as mean ± SEM. Statistical analysis: unpaired Student t-test with
Welch’s correction. *P <0.05, **P <0.01, ***P <0.001 versus vehicle-treated 3xTg-AD mice. 3xTg-AD, triple-transgenic mouse model of Alzheimer’s
disease; APP, amyloid precursor protein; C, control; ctrl, control; ELISA, enzyme-linked immunosorbent assay; I, human intravenous immunoglobulin;
IVIg, human intravenous immunoglobulin; NonTg, non-transgenic; NTg, non-transgenic; RLU, relative luminescence unit.
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along with limited activity on non-amyloid pathological
hallmarks of AD.
IVIg corrects the immunological defects in 3xTg-AD mice
and decreases CX3CR1 cell populations in the bone
marrow
A growing number of studies show an association
between neurodegenerative processes and immune
changes, both in the central nervous system (CNS) and
in the periphery [26], and genetic studies indicate that
markers of immunity such as variants of complement re-
ceptor 1, triggering receptor expressed on myeloid cells
2 (TREM2) and clusterin genes are risk factors for late-
onset AD [27-29]. More specifically, systemic immunity
and inflammation are involved in progression of the
pathology in the 3xTg-AD model [30]. Therefore, we in-
vestigated the peripheral leukocyte cell populations in
the blood of 3xTg-AD mice. Compared with NonTg
mice, total leukocytes and lymphocytes were decreased
in this model at 12 and 16 months of age (Figure 5A,B).
However, administration of IVIg for 3 months corrected
the increase of the CD4/CD8 T cell ratio observed in the
blood of 12- and 16-month-old 3xTg-AD versus NonTg
mice (Figure 5). We next analyzed markers of brain
immune response in IVIg-treated 3xTg-AD animals.
We first observed microglial activation in the vicinity
of amyloid plaques in both control and IVIg-treated
3xTg-AD mice (Figure 6A), as previously reported in the
same model [31,32]. Multiplex ELISA probing unveiled
higher levels of pro-inflammatory cytokines IL-5, IL-12,
GM-CSF and MCP-1 in the cortex of 12-month-old
3xTg-AD mice, compared to NonTg, when expressed as
ratios relative to the anti-inflammatory cytokine IL-10
(Figure 6B). Interestingly, following a 3-month IVIg
treatment, IL-5/IL-10 and IL-12/IL-10 cortical ratios in
3xTg-AD mice were brought back to levels comparable
to those in NonTg animals (Figure 6B). Although
markers of astrogliosis (glial fibrillary acidic protein(GFAP)) and the transcription factor nuclear factor-
kappa B (NF-κb) remained unaffected by the IVIg treat-
ment, in 16-month-old mice, it significantly decreased
the levels of chitinase 3-like protein 1 (YKL-40), a pro-
tein possibly involved in the neuroinflammatory re-
sponse [33], as determined by immunoblot analyses of
cortex extracts from 3xTg-AD mice (Figure 6C). Taken
together, these data thus point to a positive action of
IVIg in the control of immune homeostasis.
The fractalkine receptor CX3CR1 is expressed in spe-
cific subsets of lymphocytes, natural killer cells and
monocytes [34]. The impact of CX3CR1 on neurodegen-
eration is still debated, but previously published data
demonstrate a reduction of amyloid deposits and neur-
onal loss, and increased in vitro phagocytosis in knock-
out animals for CX3CR1 [35-37]. When measured by
Western blot analysis, expression levels of CX3CR1 and
its ligand, fractalkine, were not modulated in the cortex
of 3xTg-AD mice following a 3-month treatment with
IVIg (Figure 6D). However, flow cytometry analyses re-
vealed a 13% decrease in total CX3CR1+ cells in the
bone marrow from 3xTg-AD mice treated from 9 to
12 months of age (Figure 7A). Consistent with this,
an 11% decrease in the percentage of CX3CR1+ mono-
cytes was also observed following the same treatment
(Figure 7B). Intriguingly, this reduction was correlated
with changes in soluble and insoluble Aβ42/Aβ40 ratios
as well as Aβ*56 concentration in the brain (Figure 7C),
implying that bone marrow cells with the decreasing ex-
pression of CX3CR1 might be linked to the reduction of
cortical Aβ pathology. Such a modulation of fractalkine
signaling may represent a pathway through which IVIg
exerts its effects and support a pharmacological inter-
vention targeting CX3CR1 in AD.
Discussion
Our results are consistent with IVIg-induced improvement
of behavioral function, reduction of Aβ*56 oligomer levels
and immunomodulation in the 3xTg-AD mouse model,
Figure 4 Lack of effects of IVIg on tau pathology in 3xTg-AD
mice. (A) Brain sections of 12-month-old mice at sacrifice (n = 3 per
group) were stained for tau using anti-human tau antibody (HT-7)
after a 3-month treatment with IVIg or vehicle (ctrl) and imaged with
fluorescence. Sections shown are from the CA1 region of the
hippocampus (bregma approximately −3.5). Scale bar = 100 μm. Green,
human tau; blue, DAPI. (B) Immunoblot analyses were performed on
protein fractions from the parietotemporal cortex of 3xTg-AD mice.
Ratios of phosphorylated tau/human total tau showed the absence of
protective effects of IVIg injections. Total human tau and phosphorylated
tau were analyzed in the cytosolic (left) and insoluble fractions (right).
Representative results are presented for mice treated for 3 months and
sacrificed at the age of 12 months and 16 months (n = 10 to 13 animals
per group). Values are expressed as the mean ± SEM. Statistical
analysis: unpaired Student t-test with Welch’s correction. Examples
of immunoblots in both fractions (bottom). The homogeneity of
sample loading in cytosolic fraction was determined by protein
quantification and actin staining. 3xTg-AD, triple-transgenic mouse model
of Alzheimer’s disease; ctrl, control; DAPI, 4′, 6-diamidino-2-phenylindole;
IVIg, human intravenous immunoglobulin.
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pathology. To our knowledge, this is the first demonstra-
tion that chronic administration of IVIg can strikingly
decrease levels of the pathogenic oligomer Aβ*56 in associ-
ation with reduced expression of peripheral CX3CR1 and
attenuation of behavioral deficits in a mouse model of AD.
IVIg also displayed strong immunomodulatory properties,
leading to a correction of immune abnormalities frequently
observed in AD and animal models.
The use of IVIg in AD was initially motivated by the hy-
pothesis that it contains natural, polyclonal, conformation-
specific antibodies against Aβ. This view is supported by
the lower titer of anti-Aβ antibodies found in the blood of
AD patients compared to controls [8,9]. We thus analyzed
the impact of IVIg on various parameters of brain amyloid
pathology and found no significant reduction of either
Aβ40 or Aβ42 in both soluble and insoluble protein frac-
tions from treated mice, consistent with a recent report in
which IVIg treatment in the AβPPswe/PS1ΔE9 mouse
model of AD failed to decrease Aβ concentrations in the
hippocampus [38]. However, we observed a 22% decrease
in the soluble Aβ42/Aβ40 ratio following IVIg treatment in
16-month-old 3xTg-AD mice. This finding is interesting in
view of the fact that, in familial AD, most known APP mu-
tations increase the Aβ42/Aβ40 ratio without necessarily
changing the total concentration of Aβ peptides formed,
shifting the proteolysis of APP in favor of Aβ42, which is
more prone to oligomerization [39]. Furthermore, an
in vitro study of APP and Aβ processing in familial AD in-
dicates that the Aβ42/Aβ40 ratios correlate inversely with
the age of onset of AD [40]. In the Tg2576 mouse, a reduc-
tion of spine density, a decline in long-term potentiation,
fear conditioning impairments and an increase in Aβ42/
Aβ40 ratio precede amyloid plaque deposition [41]. More-
over, an approximate 30% increase in the insoluble Aβ42/
Aβ40 ratio is associated with spatial memory deficits fol-
lowing a partial loss of glutamate transporter 1 in the
AβPPswe/PS1ΔE9 mouse model [42]. Consistent with
these findings, a substantial decrease in the soluble Aβ*56
oligomer species was also observed in IVIg-treated 3xTg-
AD mice. There is no consensus on the actual relevance
and toxicity of the various Aβ oligomers associated with
AD pathogenesis. The Aβ*56 species are found at the AD
synapses [43] and are elevated in the CSF of cognitively
normal adults at greater risk for AD [44]. In animal
models, intracerebral administration of Aβ*56 produces
cognitive impairments in a concentration-dependent man-
ner [45,46]. In addition, Aβ*56 levels show a better associ-
ation with learning/memory deficits than plaque load [25]
in most transgenic AD models. Finally, in cognitively intact
elderly subjects, Aβ*56 correlates positively with soluble
pathological tau species and negatively with the postsynap-
tic proteins, drebrin and fyn kinase, suggesting that Aβ*56
may play a pathogenic role very early in the pathogenesis
Figure 5 IVIg injection modulates the relative populations of T lymphocytes. Flow cytometry analysis of blood cells labeled for leukocytes
(CD45), lymphocytes (B220 for B cells and CD3 for T cells), helper (CD4) and cytotoxic (CD8) T cells, and granulocytes (Gr-1). Mice were exposed
to IVIg for 3 months and sacrificed at the age of (A) 12 months and (B) 16 months. Results are presented as the mean ± SEM (n = 8 NonTg and
n = 11 to 13 3xTg-AD animals per group). Statistical analysis: one-way ANOVA followed by Tukey’s multiple comparison test. *P <0.05, **P <0.01,
***P <0.001 versus NonTg group; ##P <0.01 versus control 3xTg-AD. 3xTg-AD, triple-transgenic mouse model of Alzheimer’s disease; ANOVA, analysis of
variance; ctrl, control; IVIg, human intravenous immunoglobulin; NonTg, non-transgenic.
Table 2 Levels of proteins in the parietotemporal cortex of 3xTg-AD mice
Biological function Proteins Age group Fraction NonTg ctrl 3xTg-AD ctrl 3xTg-AD IVIg ANOVA P value
Synaptic Snap25 12 months Membrane 1.58 ± 0.38 1.48 ± 0.4 1.46 ± 0.38 0.78
PSD95 12 months Membrane 1.31 ± 0.33 1.39 ± 0.31 1.39 ± 0.33 0.85
Septin3 16 months Cytosolic 1.16 ± 0.17 1.55 ± 0.38* 1.60 ± 0.42* 0.04
Dynamin1 16 months Membrane 1.56 ± 0.23 1.38 ± 0.15 1.50 ± 0.12 0.75
Drebrin 16 months Membrane 1.35 ± 0.24 1.57 ± 0.55 1.63 ± 0.41 0.36
Synaptophysin 16 months Membrane 6.73 ± 1.5 6.86 ± 1.13 6.82 ± 1.16 0.97
Others VILIP-1 12 months Cytosolic 3.01 ± 0.59 2.68 ± 0.42 2.58 ± 0.35 0.10
VILIP-1 16 months Cytosolic 1.74 ± 0.19 1.58 ± 0.31 1.58 ± 0.25* 0.01
ADAM-10 12 months Cytosolic 8.08 ± 0.45 7.38 ± 0.23 7.55 ± 0.39 0.43
ADAM-10 16 months Cytosolic 7.97 ± 0.51 8.27 ± 0.37 7.36 ± 0.24 0.27
PAK 16 months Cytosolic 8.05 ± 2.49 6.81 ± 0.71 7.50 ± 0.93 0.07
Western blot analyses. Equal loading of samples was determined by protein quantification and actin staining. Values are expressed as the mean ± SEM of RLU
(n = 7 to 13 animals). Statistical analysis: one-way ANOVA followed with Tukey’s multiple comparison test. *P <0.05 versus NonTg ctrl; §P <0.05 versus 3xTg-AD ctrl.
3xTg-AD, triple-transgenic mouse model of Alzheimer’s disease; ADAM-10, a disintegrin and metalloproteinase domain containing protein 10; ANOVA, analysis of
variance; ctrl, control; IVIg, human intravenous immunoglobulin; NonTg, non-transgenic; PAK, p21-activated kinase; PSD95, postsynaptic density protein 95; RLU,
relative luminescence unit; Snap25, synaptosomal-associated protein 25; VILIP-1, visinin-like protein-1.
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Figure 6 Neuroimmunomodulation following IVIg treatment. (A) Brain sections of 12-month-old female 3xTg-AD mice (3-month treatment
with IVIg or ctrl) were stained and imaged with fluorescence. Iba1 (microglial cells, red), human APP/Aβ (6E10 antibody, green), DAPI (blue).
Sections shown are from the subiculum of the hippocampal formation. Blue, DAPI. Scale bar = 35 μm. Right: graph of the area occupied by Iba1
staining in amyloid plaques (n = 4 per group). Student t-test. P = 0.94. (B) Multiplex ELISA was used to quantify the cytokine levels in the parietotemporal
cortex of 12-month-old mice (3-month treatment). The values were normalized to IL-10 concentrations (n = 7 to 8 NonTg, n = 10 to 12 ctrl and
n = 12 to 13 IVIg animals per group). Data were analyzed using a Kruskal–Wallis test followed by Dunn’s multiple comparison test. *P <0.05, **P <0.01,
***P <0.001 versus NonTg group; ##P <0.01 versus 3xTg-AD control group. (C) Inflammation markers and (D) fractalkine pathway in the cortex of mice
treated with IVIg. One-way ANOVA with Tukey’s multiple comparison test. *P <0.05 versus NonTg group; #P <0.05 versus 3xTg-AD control group. (C,D)
Immunoblot analyses. Left panels: mice treated from 9 to 12 months (n = 8 NonTg, n = 12 ctrl and n = 13 IVIg animals per group). Right panels: mice
treated from 13 to 16 months (n = 7 to 8 NonTg, n = 12 to 13 ctrl and n = 13 to 14 IVIg animals per group). 3xTg-AD, triple-transgenic mouse model of
Alzheimer’s disease; APP, amyloid precursor protein; ctrl, control (vehicle); DAPI, 4′, 6-diamidino-2-phenylindole; ELISA, enzyme-linked immunosorbent
assay; GFAP, glial fibrillary acidic protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; Iba1, ionized calcium-binding adaptor
molecule 1; IL, interleukin; IVIg, human intravenous immunoglobulin; MCP-1, monocyte chemoattractant protein-1; NF-κb, nuclear factor-kappa
B; NonTg, non-transgenic.
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http://www.jneuroinflammation.com/content/11/1/54of AD [47]. The present data, in line with lower incidence
rate of dementia in IVIg-treated patients [15], suggests that
IVIg impedes accumulation of Aβ oligomers possibly by aneffect on their production, aggregation, degradation or
clearance, and might prevent AD in the pre-clinical stage.



























































































Bone Marrow cells Monocytes
Figure 7 Modulation of the fractalkine pathway by IVIg
treatment: correlation with cortical Aβ42/Aβ40 ratios and Aβ*56.
Expression of CX3CR1 was evaluated using flow cytometry in the bone
marrow of 3xTg-AD mice treated with IVIg from 9 to 12 months.
Decreases in the percentage of CX3CR1+ cells in (A) total bone marrow
cells and (B) the monocyte population were observed in treated
animals (n = 11 to 12). (C) The percentage of CX3CR1+ cells in the
bone marrow correlated with soluble and insoluble Aβ42/Aβ40
ratios (in IVIg-treated mice) and Aβ*56 concentrations from the
parietotemporal cortex (in control and total animals). Statistical
analysis: (A,B) one-way ANOVA with Tukey’s multiple comparison
test. *P <0.05. (C) Correlations were determined by simple linear
regression analysis. 3xTg-AD, triple-transgenic mouse model of
Alzheimer’s disease; ANOVA, analysis of variance; IVIg, human
intravenous immunoglobulin.
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levels of Aβ40 and Aβ42 peptides in the AβPPswe/PS1ΔE9
mouse model following an 8-month treatment with IVIgthat would be consistent with decreased Aβ oligomer/
monomer ratio following IVIg injections.
In addition to its anti-Aβ action, it can be hypothesized
that the immunomodulatory effect of IVIg contributes to
its effect in the CNS [8]. Indeed, IVIg administration in-
creases C5a brain levels [48] and reduces the expression
of the CD45 marker in a sub-population of microglial cells
in mice, in association with increased neurogenesis [38].
We found that chronic IVIg treatment steadily decreases
the CD4/CD8 cell ratio in 3xTg-AD mice, as previously
reported in a mouse model of Parkinson’s disease [24].
Such a decrease in the CD4/CD8 cell ratio was also re-
ported in IVIg-treated patients [49], suggesting that it may
actually provide a clinically relevant index of IVIg efficacy.
Interestingly, the natalizumab-induced decrease in CD4/
CD8 ratio in multiple sclerosis patients is significantly re-
lated to clinical response [50,51]. In AD patients, however,
the actual relevance of the CD4/CD8 ratio is still much
debated. Indeed, increased [52,53], unchanged [54] and
even decreased [55] CD4/CD8 ratios have been reported
in AD patients compared to controls. Thus, the clinical
implications for AD progression of the IVIg-induced de-
crease of the CD4/CD8 ratio observed here remain to be
further established. We also report evidence that IVIg de-
creases the protein levels of YKL-40 in the cortex of older
mice. Although the function of YKL-40 is still under
study, it has been associated with local neuroinflammation
in acute and chronic diseases [33], and is increased in the
CSF of AD patients [56]. We also report altered pro/
anti-inflammatory ratios of cytokines and chemokines
in 3xTg-AD mice. In agreement with the extensive body
of evidence showing an imbalance in cytokine and/or
chemokine production in the blood, CSF or brain of in-
dividuals diagnosed with AD [57], we observed a rise in
the ratios of IL-5, IL-12, MCP-1 and GM-CSF over IL-
10 in the brain of 3xTg-AD mice. Furthermore, al-
though IVIg treatment had no effect on GM-CSF/IL-10
and MCP-1/IL-10, it reduced both IL-5/IL-10 and IL-
12/IL-10 ratios. Atopy is a genetic predisposition to
hypersensitivity reactions against common environmen-
tal allergens, which manifests itself as asthma, derma-
titis or rhinitis [58]. Whereas an increased IL-5/IL-10
ratio has been reported in patients with atopic asthma
[59], atopy itself is associated with a modest rise in the risk
of dementia [58], in support of an inflammatory compo-
nent in the etiology of neurodegenerative dementia.
Finally, recent studies have linked the anti-inflammatory
effects of IVIg to terminal α2,6-linked sialic acid residues
on the N-linked glycans of a sub-population of the
IgG fragment crystallizable (Fc) domain [60-62]. These
sialylated IgG bind to the human receptor dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN) or its murine orthologue, specific
intracellular adhesion molecule-grabbing non-integrin
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immune diseases, this interaction leads to the expression
of anti-inflammatory cytokines and receptors [61]. There-
fore, sialylated IgG might recapitulate the immunosup-
pressive action of IVIg. If confirmed, the sialylated
fraction could provide a suitable alternative to this blood-
derived product. Interestingly, the SIGN-R1 receptor is
also expressed on mouse microglia [63] and therefore
could interact with sialylated IVIg in the brain. However,
it is noteworthy that the results of IVIg treatment in the
3xTg-AD model were not limited to immunosuppression
suggesting that sialylated IVIg fractions could hardly ac-
count for all the effects observed on AD markers. Taken
together, these observations support the view that IVIg
acts, at least in part, on maintaining brain immune
homeostasis, providing a favorable environment against
neurodegenerative diseases.
The interaction between CX3CR1 and its exclusive ligand
fractalkine is required for the physiological trafficking of
circulating monocytes to organs, and is an important regu-
lator of autoimmune inflammation and antigen-specific
leukocyte recruitment from the blood and the bone
marrow to the CNS [34]. Interestingly, IVIg is used in
the treatment of idiopathic thrombocytopenic purpura
and increased expression of CX3CR1 has been observed
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Figure 8 A model for IVIg mechanisms of action in the 3xTg-AD mice
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as a new mechanism of action for IVIg. Studies on the role
of the fractalkine pathway in animal models of AD have
generated somewhat contradictory results. CX3CR1 gen-
etic depletion was found to protect from neuronal loss in
the 3xTg-AD model [37] and reduce β-amyloid deposition
by activating its phagocytosis in CRND8, APPPS1 and
R1.40 mice [35,36], whereas it exacerbates tau phosphoryl-
ation and aggregation, and enhances cognitive deficits in
hTau and hAPP mice [65,66]. These results strongly sug-
gest that CX3CR1 signaling regulates microglial activity
and neuropathological processes in AD. However, genetic
knockouts of CX3CR1 hardly mimic the actual trends
in CX3CR1 expression in physiological conditions and
during the progression of the disease. In the brain, the
fractalkine pathway mediates the communication between
neurons, which produce fractalkine, and microglia, which
express CX3CR1, as binding of the two inhibits microglial
activation [67]. In the present study, IVIg administration
had no effect on brain expression levels of CX3CR1 or
fractalkine, as detected by Western blot analysis. However,
our data show an 11 to 13% decrease in CX3CR1+ cells in
the bone marrow from IVIg-treated 3xTg-AD mice, which
was correlated with a reduction of both Aβ*56 concentra-
tion and Aβ42/Aβ40 ratios in the cortex. A recent study
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associated CD4/CD8 ratio reduction. This increase in
CD8+ T cells was associated with higher expression of
the CX3CR1 chemokine receptor and the authors sug-
gested that it could serve in the homing of T cells to the
brain parenchyma. The fact that the concentration of T
cells is low in the brain could explain our failure to detect
an increase in CX3CR1 protein levels in the IVIg-treated
mice. Therefore, the fractalkine pathway clearly warrants
further investigation as a therapeutic target of IVIg or
other compounds in neurodegenerative diseases.
Conclusion
Taken together, our results show that IVIg treatment ame-
liorates cognitive performance, decreases Aβ42/Aβ40 ra-
tios and Aβ*56 concentrations in the brain, reduces
inflammation, and modulates the expression of CX3CR1
in the bone marrow (Figure 8). These data are consistent
with biomarker analyses from the recent phase III trial on
IVIg where a dose-dependent decrease in plasmatic Aβ42
and a reduction in PET-determined [18 F]florbetapir
binding in the brain were reported [12]. In keeping with
the recent failure of anti-Aβ-based immunotherapies to
improve cognition in clinical trials [5], regulation of Aβ
pathology may not be sufficient to fully account for the
action of IVIg in AD, particularly in the absence of an
amelioration of tau pathology and synaptic defects.
Thus, a combination of these effects on Aβ pathology
and immune parameters is likely responsible for the
cognitive improvements detected in IVIg-treated 3xTg-
AD mice. More specifically, the present data provides im-
portant insights into the mechanism of action of IVIg in
AD and identifies Aβ*56 oligomers, effector T cells and
fractalkine signaling as possible targets for a pharmaco-
logical substitute for the severely limited supply of IVIg
available for AD therapy.Additional file
Additional file 1: Table S1. Antibodies used.
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